Aspirin Drug Market

Aspirin Drug Market Outlook 2024 to 2034

The global aspirin drug market share is expected to account for USD 2,938.2 million in 2024 and expand at a consistent CAGR of 3.8% to reach a valuation of USD 4,236.9 million by 2034. According to a recent study by Future Market Insights, a combination aspirin drug is leading the market with a share of about 68% in 2023 within the global market.

Growth in the aspirin industry could be attributed to an increase in conditions like arthritis, pain, and inflammation. The rising incidence of chronic conditions like renal disorders, cardiovascular diseases, and brain strokes among people is driving the aspirin drug market forward. The initiative taken by public and private organizations to spread awareness about myocardial infarction is expected to elevate the market scope further.

Data Points	Market Insights
Aspirin Drug Market Size, 2023	USD 2,831.8 million
Aspirin Drug Market Size, 2024	USD 2,938.2 million
Aspirin Drug Market Size, 2034	USD 4,236.9 million
CAGR 2024 to 2034	3.8%

Key Market Opportunities for Aspirin Drug Manufacturers

• The rising prevalence of cardiovascular disease due to changes in population lifestyle, including consumption of high-cholesterol food, smoking, and other factors, in both developing and developed countries, is offering aspirin manufacturers significant business opportunities.
• Increasing incidents of clots, heart attacks, and heart tissue destruction are inducing medical professionals to prescribe aspirin for its effectiveness in treating these issues.
• Expanding the scope of active pharmaceutical ingredients and the usage of these APIs in drug formulation. Aspirin shows its effects on COX (Cyclooxygenase) dependent and independent mechanisms, effectively preventing several diseases such as diabetes, cancer, nervous system disorders, and cryptococcal infection.
• High morbidity risk associated with blood clots is fueling the use of aspirin due to its anti-clotting properties that allow blood to flow while the patient receives alternative medical treatment smoothly. Due to this advanced use of aspirin, the market demand is predicted to continue rising.

Sales Analysis of Aspirin Drug Industry from 2019 to 2023 Vs Market Outlook for 2024 to 2034

Attributes	Details
Aspirin Drug Market Size (2019)	USD 2,471.6 million
Aspirin Drug Market Size (2023)	USD 2,831.8 million
Aspirin Drug Market CAGR % (2019 to 2023)	3.4%

The market value for aspirin drugs was around 18.6% of the overall USD 15.1 billion of the global non-steroidal anti-inflammatory drugs (NSAIDs) market in 2023.

The sale of aspirin drugs expanded at a CAGR of 3.4% from 2019 to 2023 owing to rising diseases like pain, fever, inflammation, rheumatoid arthritis, and systemic lupus erythematosus. This can be attributed to the consumption of aspirin as a blood-thinning agent in treating chronic diseases. Further, it reduces the risk of blood clot formation and treats minor pain and aches.

The aspirin drug market continues to expand due to new drug research, commercial use, and development breakthroughs. For instance, in July 2019, Dr Reddy's Laboratories launched rosuvastatin, aspirin, and clopidogrel FDC under Rozat Gold.

Over the forecast period, the market is projected to be driven by the pharmaceutical industry's rising efforts in discovering novel treatments to treat chronic diseases. The global aspirin drug market is expected to register a CAGR of 3.8% from 2024 to 2034.

Historical CAGR % (2019 to 2023)	3.4%
Forecast CAGR % (2024 to 2034)	3.8%

Country-wise Insights

The United States Holds Supremacy in Aspirin Drug Market

Country	The United States
CAGR (2024 to 2034)	3.9%

The United States is expected to seize a 25.7% global market share in 2024. Recent market projections indicate continued profitable prospects in North America. The primary driver of the target market is the increasing need for aspirin to manage chronic pain. Chronic pain, especially in adults, is rising in the United States due to sitting for an extended time. Aspirin drug acts as a painkiller for chronic pain. For instance, in a report published by the Centers for Disease Control and Prevention, a prevalence of chronic pain as well as high-impact chronic pain was found among United States adults, with 4% (50.0 million) suffering from chronic pain and 8.0% (19.6 million) from high-impact chronic pain, respectively. These are key driving factors propelling this region's demand for aspirin drugs.

Germany Witnessing Surging Research and Development Efforts to Further Enhance Versatility of Aspirin

Country	Germany
CAGR (2024 to 2034)	3.1%

In Europe, Germany is anticipated to acquire a significant share of 26.5% of the aspirin drug market in 2024. In 2024, the German aspirin drug market is predicted to reach USD 187.8 million, followed by a CAGR of 3.1% through 2034.

• The increasing density of multinational biotechnology and pharmaceutical companies is crowding the market in Germany. This is anticipated to enhance the accessibility of common drugs among the population.
• Upsurge in the development of a surprisingly versatile aspirin by leading players that not only stops pain but also prevents cardiovascular events in at-risk patients is expected to favor market growth.

Surging Diabetic Population in the United Kingdom Augmenting Aspirin Sales

Country	The United Kingdom
CAGR (2024 to 2034)	3.2%

The aspirin drug market in the United Kingdom is expected to acquire a mere 3.2% global market share in 2024. In Europe, the market share is estimated to be a notable 21.1%. After attaining a market value of USD 88.2 million in 2024, the market is expected to record a CAGR of 3.2% through 2034. The following factors support the regional growth:

• The widespread use of aspirin for migraine pain relief, headaches, joint pain, and back and muscle aches is fueling the consumption of aspirin in the country.
• The increasing diabetic population in the United Kingdom is supporting the sales of aspirin in the United Kingdom.

India Presenting a Lucrative Business Prospect for Aspirin Drug

Country	India
CAGR (2024 to 2034)	3.4%

The aspirin drug market in India is set to exhibit a CAGR of 3.4% in 2034. In India, substantial financing and the launch of several healthcare programs, like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat, which offer accessible healthcare facilities and reimbursement options to patients receiving healthcare treatment, are boosting the product demand. Other factors leading to product sales are:

• Increasing disposable income in middle-class families is enabling them to spend more on their healthcare to get high-quality treatment facilities.
• The market is expected to expand more quickly throughout the forecast period due to increased expenditure on continued research and development efforts for aspirin drug development.

Surging CVD Cases in China Enhancing Scope of Aspirin Drugs

Country	China
CAGR (2024 to 2034)	3.6%

China holds around 5.4% share in the global market in 2023, owing to the prevalence of increasing cardiovascular diseases like stroke or heart attack. China is one of the leading producers of aspirin drugs. Around two-thirds of aspirin is now produced in China. Drug development of aspirin drugs is significantly increasing in China due to rising research funding. These factors are predicted to drive sales of aspirin drugs in China. Additionally, due to the increase in the production and export of APIs, which accounts for 20% of global output, China is considered one of the top leaders in the region.

Category-wise Insights

Power of More is Propelling Consumption of Combination Aspirin Drug

Leading Product Type	Combination
CAGR	4%

The combination is anticipated to account for 68% value share in 2024. The segment is expected to display a CAGR of 4.0% through 2034. Antiplatelet agents are a class of drugs that include extended-release dipyridamole and a combination of aspirin. A combination of aspirin prevents excessive blood clotting, leading to widespread adoption.

Aspirin Tablets Find Extensive Adoption by the Patient Base

Leading Dosage Form	Tablets
Market Share % (2024)	3.4%

The tablets segment is anticipated to hold a market share of 44.8% in 2024. Over the forecast period, the segment is expected to grow gradually, with an estimated CAGR of 3.4% through 2034. Tablets are the easiest and safest way to consume the drug. Further, it helps to alleviate fever and relieve pain from conditions such as toothaches, muscle aches, and the common cold. These factors are increasing the sales of aspirin drugs in tablet form.

Patients are Increasingly Seeking Oral Routes of Administration for their Ailments

Leading Route of Administration	Oral
CAGR	3.5%

The oral route of administration usage is more as compared to rectal and parenteral. Topical holds a prominent market share value of 49.8% in 2024, followed by a CAGR of 3.5% through 2034. Owing to its advantages, such as patient compliance, non-invasiveness, and convenience of drug administration, the oral route of administration is the favored method.

The Pediatric Patient Base Substantially Contributes to the Sales of Aspirin Drugs

Leading Age Group	Pediatric
CAGR	56.2%

Pediatrics is projected to hold a market share of 56.2% in 2024. The segment is expected to grow gradually over the forecast period, with an estimated CAGR of 3.8% through 2034. Aspirin drug dosage is quite effective in pediatric populations suffering from diseases like chicken pox and flu-like symptoms. The weak immune system of the pediatric population makes them an easy target for these diseases. Hence, aspirin drug is commonly used in the medicine of the pediatric population.

Retail Pharmacies Observe Significant Sales of Aspirin Drugs

Leading Distribution Channel	Retail Pharmacies
CAGR	3.4%

Retail Pharmacies are anticipated to register a prominent share of 44.0% in the aspirin drug market in 2024, with a CAGR of 3.4% through 2034. The easy availability of drugs in all forms in retail pharmacies supports the increasing purchases of medicines from these pharmacies.

Key Strategies of Leading Players of Aspirin Drugs

The market for the production of aspirin drugs is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new drug releases to meet consumer demand and amplify their client base. Governments across the globe are also taking initiatives to invest in life-saving drugs like aspirin.

• In March 2023, the FDA approved PLx Pharma Inc., SNDAs for VAZALORE 325 mg and 81 mg. VAZALORE is a liquid-filled aspirin capsule that patients with vascular disease and diabetes consume.
• In November 2023, Janssen presented data from two latest analyses at the American Heart Association's (AHA) 2023 Scientific Sessions that reinforce critical cardiovascular and adverse limb events can be treated with XARELTO plus aspirin.

Similarly, the team at Future Market Insights has tracked recent developments related to pharmaceutical companies manufacturing aspirin drugs, which are available in the full report.

Key Players Providing Aspirin Drug

• Bayer AG
• Dr Reddy's Laboratories
• Sanofi S.A
• Abbott Laboratories
• Sunshine Laboratories India Limited
• ANI Pharmaceuticals, Inc
• Thermo Fisher Scientific,
• Advance Pharmaceutical Inc.
• Allegiant Health
• KEM Pharma LLC
• Globalimporter Inc.
• Par Pharmaceutical,
• Industria Quimica Andina Y Cia Sa
• Cardinal Health
• Nanjing pharmaceutical factory Co, ltd.
• JQC (Huayin) Pharmaceutical Co., Ltd.
• LNK International, Inc.
• Perrigo Company plc
• Zhenjiang Gaopeng Pharmaceutical CO,.Ltd.
• J.M. Loveridge Ltd
• Mayne Pharma Group Limited
• Eli Lilly and Company
• Shandong Xinhua Pharmaceutical Co Ltd
• Zhongnan Pharmaceutical
• Jilin Pharmaceutical
• Novacap
• Alfred Benzon As
• Noristan Ltd

Key Market Segments Covered in Aspirin Drug Market Research

By Product Type:

• Alone
• Combination

By Dosage Form:

• Tablet
• Capsules
• Injections
• Suppositories

By Route of Administration:

• oral
• Rectal
• Parenteral

By Age:

• Adult
• Pediatric

By Distribution channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Aspirin Drug Market?

The aspirin drug market is expected to be worth USD 2,938.2 million in 2024.

What is the Growth Potential of Aspirin Drug?

The market is predicted to expand at a CAGR of 3.8% through 2034.

What is the Future of the Aspirin Drug Market?

The market is anticipated to account for USD 4,236.9 million by 2034.

Which Country Offers High Growth Prospects for Aspirin Drugs?

China is predicted to provide high growth opportunities.

Which Product Type is Extensively Used by Patients?

Health professionals significantly prescribe combination aspirin drug.